Microglial senescence in alzheimer's disease amyloid pathology

Active Grant Awarded

Award ID
F31AG099243
Recipient
Awarding agency
Obligated
$50,114

Award facts

Assistance listing
93.866 Aging Research
Completion date 8% complete
Place of performance
Jacksonville, FL 32224, USA

Award details come from USAspending.gov.

Description

Abstract
Alzheimer's disease (ad) is a devastating neurodegenerative disease characterized by the accumulation of intracellular TAU neurofibrillary tangles and extracellular amyloid-Β (AΒ) plaques. The greatest risk factor for developing ad is aging. However, the exact mechanism of this age-related risk is still not understood. Cellular senescence, a hallmark of the aging cellular phenotype, is characterized by irreversible cell cycle arrest, resistance to apoptosis, mitochondrial stress, and increased expression of cell cycle inhibitors, such as cyclin- dependent kinase inhibitor 4/6, P16IK4A. Recently, senescence has emerged as a potential contributor to the age-related risk of developing ad. Previous studies have shown that the elimination of either senescent or P16 IK4A - expressing cells decreases pathology in the P301S mouse model of TAU pathology. Interesting, in the aging brain, microglia produce the most P16IK4A. Microglia, the brain's resident macrophages, are responsible for selective immune signaling, phagocytosis of toxic protein aggregates and cellular debris. Microglia also offer instrumental support to neurons through the release of trophic factors. Therefore, microglia dysfunction would likely be detrimental in the context of ad. However, whether microglial P16IK4A expression drives the age-related risk of ad has yet to be determined and provides the basis of this proposal. We hypothesize that, throughout aging, P16IK4A expression increases within microglia, leading to a senescent phenotype and microglia-specific molecular changes. Such changes lead to dysfunction, such as a nonselective proinflammatory immune response, a loss of trophic support, and decreased phagocytotic ability; all of which aid in driving the age-related risk of ad. We will assess this hypothesis in the following two aims: 1) define the molecular and function impact of P16IK4A- induced senescence in ipsc-derived microglia and 2) determine the role of microglia-specific P16IK4A expression using amyloid model 5XFAD mice. To achieve these aims, we have leveraged innovative ipsc technology, combined with piggybac transposition, to develop monoclonal ipsc colonies containing a stably integrated doxycycline-inducible P16IK4A expression construct. Upon doxycycline administration, these ipscs display a senescent phenotype. Additionally, we have developed a microglia-specific P16IK4A expression mouse model by leveraging a novel breeding scheme and incorporating the 5XFAD mouse model into our experimental design. We have validated that this model shows microglia specificity and high efficiency. These complimentary in vitro and in vivo approaches, combined with single-cell RNA sequencing, will allow for the comprehensive assessment of microglial P16IK4A expression in the context of AΒ pathology. This project will be the first of its kind to investigate the connection between phenotypic changes and cell specific gene expression in senescent microglia. Results from these studies will help identify novel therapeutic targets and pathways, and thus elucidate how senescent microglia contribute to the age-related risk of ad.

Transactions

Action Obligated Date
Amendment $50,114
Original award $0

Quick answers

Who received award F31AG099243?

F31AG099243 was awarded to Mayo Clinic Jacksonville (A Nonprofit Corporation) by National Institute on Aging (National Institutes of Health) on September 14, 2026.

How much is award F31AG099243 worth?

$50,114 has been obligated on F31AG099243.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award